Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 27,061 Bruker Corporation $BRKR

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 27,061 shares of the medical research company’s stock, valued at approximately $1,629,000.

Several other institutional investors have also recently made changes to their positions in BRKR. Thrivent Financial for Lutherans grew its position in Bruker by 561.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 179,792 shares of the medical research company’s stock worth $8,470,000 after buying an additional 152,603 shares in the last quarter. Hantz Financial Services Inc. increased its stake in Bruker by 202.7% in the 4th quarter. Hantz Financial Services Inc. now owns 41,306 shares of the medical research company’s stock worth $1,946,000 after acquiring an additional 27,659 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Bruker by 317.7% in the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after acquiring an additional 1,756,460 shares in the last quarter. Fifth Third Bancorp grew its holdings in shares of Bruker by 4,058.3% during the first quarter. Fifth Third Bancorp now owns 57,135 shares of the medical research company’s stock worth $2,064,000 after purchasing an additional 55,761 shares in the last quarter. Finally, Amundi grew its holdings in shares of Bruker by 244.2% during the first quarter. Amundi now owns 62,611 shares of the medical research company’s stock worth $2,261,000 after purchasing an additional 44,421 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

Shares of Bruker stock opened at $59.56 on Friday. The firm has a market capitalization of $9.07 billion, a PE ratio of -85.09, a price-to-earnings-growth ratio of 1.83 and a beta of 1.28. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $65.30. The business’s 50-day moving average price is $58.66 and its 200-day moving average price is $47.48.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 21st. Bruker’s payout ratio is presently -28.57%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Guggenheim raised their target price on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. JPMorgan Chase & Co. boosted their price target on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Barclays raised their price objective on shares of Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $56.64.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.